Mayank Gandhi - 17 Jan 2023 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Reporting relationship: Chief Business Officer
Issuer ticker: N/A
Reported as of: 17 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jan 2023, 16:04:30 UTC
Prior SEC filing: 28 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Byrnes, Attorney-in-Fact for Mayank Gandhi

Key filing fact

Mayank Gandhi filed Form 4 for eFFECTOR Therapeutics, Inc. on 19 Jan 2023.

Key facts

This page summarizes Mayank Gandhi's Form 4 filing for eFFECTOR Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Jan 2023, 16:04.

Change

Previous filing in this sequence was filed on 28 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EFTR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 17 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.4700
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 17, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.